LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

Dr. Chapin and fellow expert oncologists discuss the latest data from the LIGHTHOUSE trial, evaluating 18F-rhPSMA-7.3 for staging patients with prostate cancer.

EP: 1.The Evolution of Imaging Techniques in Prostate Cancer

EP: 2.The Utility of PSMA PET in Prostate Cancer

EP: 3.Clinical Development of PSMA-Targeted Therapies

EP: 4.Clinical Practices of PSMA-Targeted Agents in Prostate Cancer

EP: 5.Multidisciplinary Approaches in PSMA PET for Prostate Cancer

EP: 6.Patient Profile 1: A 51-Year-Old Man with High-Risk Localized Prostate Cancer

EP: 7.PSMA PET Imaging and Clinical Perspectives from Patient Profile 1

Now Viewing

EP: 8.LIGHTHOUSE Trial and The Role of 18F-rhPSMA-7.3 for Staging of Prostate Cancer

EP: 9.An Overview of the SPOTLIGHT Trial for PSMA PET in Prostate Cancer

EP: 10.SPOTLIGHT Trial and 18F-rhPSMA-7.3 for Prostate Cancer

EP: 11.Patient Profile 2: A 62-Year-Old Man with Recurrent Prostate Cancer

EP: 12.Patient Profile 3: A 67-Year-Old Male with Recurrent Prostate Cancer

EP: 13.Future Horizons in PSMA-Targeted Imaging and the Management of Prostate Cancer

Related Videos

Related Content

Advertisement

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

December 28th 2024

Top 10 prostate cancer articles and videos of 2024

Benjamin P. Saylor

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

Related Content

Advertisement

January 15th 2025

EU approves Mona Lisa 2.0 robotic system for prostate cancer

Hannah Clarke

The Mona Lisa 2.0 platform has been previously approved in the US, Australia, and Singapore.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 9th 2025

Dual-masked PSMA-targeting T-cell engager shows promise in mCRPC

Hannah Clarke

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

December 28th 2024

Top 10 prostate cancer articles and videos of 2024

Benjamin P. Saylor

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.